Gilead Sciences to donate Truvada for PrEP® to U.S. CDC

Pharmaceutical

Around 1.1 million Americans are at risk of HIV, of which just circa 200,000 currently receive Truvada for PrEP for a variety of reasons from homophobia to limited awareness of PrEP among providers and patients. Gilead Sciences has announced its intention to make a donation designed to help reach these people and ensure uninsured people at risk for HIV are given access to PrEP at no cost. The company plans to donate up to 2.4 million bottles of Truvada for PrEP every year until 2030 to the U.S. Centers for Disease Control and Prevention to help prevent HIV. This donation forms part of Gilead’s wider initiatives to help ensure that everyone who can benefit from PrEP gets access to it.

“Gilead Sciences to donate Truvada for PrEP® to U.S. CDC.“

Gregg Alton, Chief Patient Officer at Gilead Sciences, said: “We are proud to partner with CDC to dramatically expand access to medication that can help prevent new HIV infections. We believe today’s donation, combined with efforts to address the root causes of the epidemic, such as racism, violence against women, stigma, homophobia and transphobia, can play an important role in ending the HIV epidemic in the United States, particularly in parts of the country with the highest burden of disease.”

See all the latest jobs in Pharmaceutical
Return to news